Adipocyte-like signature in ovarian cancer minimal residual disease identifies metabolic vulnerabilities of tumor-initiating cells
Mara Artibani(University of Oxford), Ahmed A. Ahmed(St. George's University), Abdulkhaliq Alsaadi(University of Oxford), Laura Santana González(University of Oxford), Takeshi Motohara(Kumamoto University), Robin W. Klemm(University of Oxford), Matteo Morotti(University Hospital of Lausanne), Stephen Damato(Oxford University Hospitals NHS Trust), Salma El-Sahhar(University of Oxford), Christos E. Zois(Democritus University of Thrace), Alexandros Laios(Churchill Hospital), Mohammad KaramiNejadRanjbar(University of Oxford), Tatjana Sauka‐Spengler(MRC Weatherall Institute of Molecular Medicine), Pubudu Pathiraja(Churchill Hospital), Nina Wietek(Churchill Hospital), Ashwag Albukhari(King Abdulaziz University), Kenta Masuda(Keio University), Robert C. Bast(Fox Chase Cancer Center), Sarah P. Blagden(Churchill Hospital), Pascal C. Rauher(University of Zurich), Fergus Gleeson(Churchill Hospital), Shibani Nicum(London Cancer), Adrian L. Harris(University of Oxford), Christer S. Ejsing(University of Southern Denmark), Christopher Yau(University of Leeds), Zhen Lü(The University of Texas MD Anderson Cancer Center), Sunanda Dhar(Oxford University Hospitals NHS Trust), Kay Y. Chong(Guangxi Medical University), Garry Mallett(University of Oxford), Leticia Campo(University of Oxford), Zhiyuan Hu(Fujian Medical University)
Cited by 42
Related Papers
Rethinking ovarian cancer: recommendations for improving outcomes
|Nature reviews. Cancer|2011|1.5k
Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer
|Nature reviews. Cancer|2015|1.4k
ESMO–ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease
|Annals of Oncology|2019|1.2k